Rifaximin

Introduction Overview

Generic Name

rifaximin

Brand Name

Xifaxan

Dosage Form

Oral tablet

Drug Class

Miscellaneous antibiotics

Pharmacokinetics

Absorption:
Rifaximin exhibits minimal systemic absorption following oral administration, primarily exerting its antimicrobial effects locally within the gastrointestinal tract. Studies indicate that less than 0.4% of the administered dose is absorbed into the bloodstream, making rifaximin a minimally absorbed antibiotic. This limited absorption is attributed to its structural properties and poor solubility, restricting its diffusion across the intestinal mucosa. The drug's efficacy stems from its high local concentrations in the intestinal lumen rather than systemic circulation. Food intake does not significantly alter rifaximin bioavailability, allowing flexible dosing concerning meals. Clinically, this characteristic reduces systemic toxicity and drug interactions associated with blood exposure.

Distribution:
Due to its negligible systemic absorption, rifaximin remains predominantly within the gastrointestinal tract with minimal distribution to peripheral tissues or organs. Plasma protein binding is low, consistent with the minimal detected plasma concentrations. The drug’s confinement to the gut lumen allows for targeted treatment of intestinal infections without significant exposure to other body tissues. In patients with liver impairment, accumulation outside the gut remains minimal, further supporting its favorable safety profile.

Metabolism:
Rifaximin undergoes negligible systemic metabolism owing to its poor absorption. The antibiotic remains largely unchanged within the intestinal tract. There is minimal hepatic metabolism, and systemic enzymatic conversion is not a significant pathway. This lack of metabolism contributes to the drug's stability and localized action. Research suggests that intestinal flora may partially degrade rifaximin; however, detailed metabolic pathways remain under investigation. The absence of hepatic metabolites reduces the risk of hepatic drug interactions.

Elimination:
Excretion of rifaximin is primarily via feces, with nearly 97% of an orally administered dose recovered unchanged in fecal matter. Due to minimal systemic absorption, renal excretion is insignificant. This predominant fecal elimination confirms the drug's localization to the gastrointestinal tract. Renal impairment does not constitute a dosage adjustment consideration. The elimination profile ensures sustained luminal concentrations effective against pathogenic bacteria while minimizing systemic exposure and toxicity.

Dosage Forms

Available Dosage Forms:
- Oral tablet formulations of 200 mg and 550 mg strength are commercially available.

Dosages for Adults and Adolescents:
- Traveler's Diarrhea: 200 mg orally three times daily for 3 days; used to treat noninvasive strains of Escherichia coli.
- Hepatic Encephalopathy: 550 mg orally twice daily for long-term prevention of overt hepatic encephalopathy recurrence; often used concomitantly with lactulose.
- Irritable Bowel Syndrome with Diarrhea (IBS-D): 550 mg orally three times daily for 14 days; repeat courses allowed up to two times if symptoms recur.
- Adolescents (12 years and older) receive dosing analogous to adults for traveler’s diarrhea indication (200 mg orally three times daily for 3 days).

Specific Patient Populations:
- Use in children under 12 years of age is not recommended due to lack of sufficient safety and efficacy data.
- No specific dosage adjustments are described for hepatic or renal impairment given minimal systemic absorption; however, caution advised in severe liver disease.
- For patients with diarrhea complicated by fever, bloody stools, or caused by pathogens other than E. coli, rifaximin is not indicated.
- Flexible administration with or without food is permissible, enhancing patient adherence.

Mechanism Of Action

Rifaximin exerts its antibacterial effect by targeting bacterial RNA synthesis through binding to the β-subunit of bacterial DNA-dependent RNA polymerase. This interaction inhibits the transcription process, effectively preventing the synthesis of essential RNA molecules needed for bacterial protein production and replication. By interfering with RNA synthesis, rifaximin halts bacterial proliferation and eradicates pathogenic organisms within the gut.

Uniquely, rifaximin’s structure confers minimal systemic absorption, concentrating its activity within the gastrointestinal lumen. This local effect allows for treatment of intestinal infections without systemic toxicity typically associated with broad-spectrum antibiotics. Rifaximin’s mechanism is distinct from other antibiotics that inhibit cell wall synthesis or protein synthesis, providing an alternative modality particularly effective against enteric bacteria.

At the cellular level, rifaximin's action on RNA polymerase is bactericidal against susceptible bacteria such as Escherichia coli, the primary pathogen implicated in traveler’s diarrhea, and modulates gut microbiota composition. Beyond direct antimicrobial activity, rifaximin may reduce bacterial translocation and endotoxin load, which is proposed to contribute to its efficacy in hepatic encephalopathy by decreasing the production of gut-derived neurotoxins implicated in brain dysfunction.

Comparatively, rifaximin’s low absorption differentiates it from systemic rifamycins like rifampin. This pharmacologic profile reduces adverse systemic effects and drug interactions, making rifaximin uniquely suited for gastrointestinal pathologies. Clinical trials have substantiated the role of rifaximin in reducing diarrhea duration and improving symptoms of IBS-D and hepatic encephalopathy through these localized mechanisms.

Pharmacological Actions

Selective bactericidal activity through inhibition of bacterial RNA synthesis.
Targets intestinal pathogens by binding bacterial DNA-dependent RNA polymerase.
Exhibits broad spectrum activity against Gram-positive and Gram-negative enteric bacteria, including Escherichia coli.
Minimal systemic absorption allows localized gastrointestinal action with limited systemic exposure.
Modulates gut microbiota composition, potentially restoring balance in gastrointestinal disorders.
Reduces bacterial translocation and endotoxin production contributing to hepatic encephalopathy management.
Does not significantly impact systemic bacterial flora, reducing risk of systemic antibiotic resistance.
Effective in decreasing intestinal inflammation and permeability associated with IBS-D.
Exhibits stability in the acidic gastric environment, ensuring delivery to the distal intestine.
Shows lack of significant systemic metabolism and drug interactions relative to other rifamycins.
Provides a favorable safety profile due to minimal absorption and targeted site of action.
Can be repeatedly administered in clinical practice for recurrent IBS-D symptoms without systemic toxicity.
Used adjunctively with lactulose for synergistic effect in preventing hepatic encephalopathy recurrence.
Demonstrates efficacy in noninflammatory traveler’s diarrhea caused by noninvasive E. coli strains.

Therapeutic Or Clinical Uses

Treatment of traveler’s diarrhea caused by noninvasive strains of Escherichia coli in adults and children aged 12 years and older.
Management of irritable bowel syndrome with diarrhea (IBS-D) in adult patients to reduce symptoms and improve quality of life.
Reduction in the risk of overt hepatic encephalopathy recurrence in adults with liver failure, improving neurological outcomes.
Off-label use in modulating gut microbiota in specific gastrointestinal infections or disorders (pending clinical judgment).
Adjunct therapy with lactulose in hepatic encephalopathy to enhance efficacy and prevent neurocognitive decline.
Treatment of mild to moderate intestinal bacterial infections localized to the gastrointestinal tract without systemic involvement.
Therapeutic option for patients intolerant to other systemic antibiotics for intestinal infections due to minimal absorption.
Useful in patients requiring antibiotic therapy with reduced risk of systemic adverse effects.
Employed to reduce bacterial translocation and enteric endotoxemia in chronic liver disease management.
Management of symptoms associated with small intestinal bacterial overgrowth (SIBO) in clinical practice.
Utilized in patients with contraindications to other antibiotics due to safety or drug interaction concerns.
Can be used repeatedly for recurrent IBS-D episodes under medical supervision without increasing systemic toxicity risks.

Side Or Adverse Effects

Swelling of hands or feet (peripheral edema) observed in some patients.
Nausea, potentially mild and transient during therapy.
Headache and dizziness reported, indicating neurological mild adverse reactions.
Tiredness or fatigue during treatment periods.
Abnormal liver function tests including transient elevations in hepatic enzymes.
Rare incidence of allergic reactions including urticaria, facial swelling, or angioedema requiring immediate medical attention.
Potential development of watery or bloody diarrhea, possibly indicative of superinfection or Clostridioides difficile-associated diarrhea.
Severe stomach pain accompanied by diarrhea may signal serious gastrointestinal complications.
Fluid accumulation in the abdomen (ascites) with rapid weight gain and abdominal bloating reported in patients with hepatic impairment.
Local gastrointestinal discomfort such as bloating or cramping may occur.
Rare risk of developing antibiotic resistance with inappropriate or incomplete use.
Hypersensitivity reactions especially in patients allergic to rifamycin antibiotics.
Transient taste disturbances during therapy reported anecdotally.
No significant systemic toxicities due to negligible absorption.
Possibility of emergence of new infections due to alteration of gut flora.

Precautions

Avoid use in patients with known allergy to rifaximin or other rifamycin antibiotics such as rifampin, rifabutin, or rifapentine.
Exercise caution in patients with severe liver disease and monitor liver function tests regularly.
Do not use in patients presenting with diarrhea complicated by fever or bloody stools without appropriate medical evaluation.
Pregnant or breastfeeding women should use only if clearly needed and as advised by a healthcare provider.
Not recommended in children under 12 years of age due to insufficient safety and efficacy data.
Use full prescribed courses to minimize development of bacterial resistance and treatment failure.
Monitor patients for signs of superinfection or Clostridioides difficile–associated diarrhea during or after therapy.
Use caution when co-administered with other antibiotics or medications with potential overlapping toxicities.
Advise patients to report any severe abdominal pain, worsening diarrhea, or allergic reactions promptly.
Consider potential interactions with cyclosporine, warfarin, ketoconazole, and certain antiviral or cardiac medications.
Adjust clinical monitoring in patients with compromised renal or hepatic function despite minimal systemic absorption.
Use with caution in patients with a history of antibiotic-associated colitis or gastrointestinal disease.
Educate patients not to share medication to reduce risk of inappropriate use and resistance.
Avoid treatment of diarrhea caused by viral infections to prevent unnecessary antibiotic exposure.
Storage at room temperature away from moisture and heat to maintain drug stability.

Warnings

Contraindicated in patients allergic to rifaximin or rifamycin-related antibiotics such as rifampin.
Not effective against all forms of traveler’s diarrhea; ineffective for infections caused by pathogens other than noninvasive E. coli.
Should not be used for diarrhea accompanied by fever, or watery or bloody stools without medical advice.
Risk of developing antibiotic-resistant bacteria if course is not completed as prescribed.
Potential for severe hypersensitivity reactions necessitating emergency medical care.
Use with caution in severe liver impairment; monitor for fluid accumulation and worsening hepatic encephalopathy.
Xifaxan does not treat viral infections; misuse may delay appropriate treatment.
Patients should be monitored for signs of Clostridioides difficile infection, given the risk of antibiotic-associated colitis.
Do not use in children under 12 years old due to lack of safety data.
Discontinue if signs of allergic reaction or severe adverse reactions occur.
Concurrent use with other drugs should be monitored due to possible drug interactions despite minimal systemic absorption.
Patients should be advised to seek immediate care for signs of worsening symptoms or new infections.
Not indicated for systemic infections due to poor systemic bioavailability.
Use only under proper medical supervision for intended indications.
Avoid use in diarrhea caused by invasive bacteria or complicated infections.

Contraindication

Hypersensitivity to rifaximin or any rifamycin antibiotic including rifampin, rifabutin, or rifapentine.
History of allergic reaction to rifaximin or related compounds.
Patients with diarrhea complicated by fever and/or bloody stools before initiating therapy.
Known invasive bacterial gastrointestinal infections requiring systemic antibiotic therapy.
Pediatric patients under 12 years of age due to unestablished safety and efficacy.
Patients with known severe hepatic impairment without close medical monitoring.
Use in viral diarrhea infections is contraindicated due to lack of efficacy.
Known hypersensitivity to any excipients in the rifaximin formulation.
Concurrent use with certain systemic drugs may be contraindicated without proper medical supervision.
Prior history of antibiotic-associated colitis directly contraindicates use without evaluation.
Use contraindicated when treating infections requiring systemic antibiotic concentrations.
Known pregnancy or breastfeeding cases discouraged unless benefit outweighs potential risks.

Drug Interactions

Cyclosporine may increase rifaximin intestinal concentrations; concomitant use requires monitoring.
Ketoconazole and other antifungals can affect intestinal flora and interact pharmacodynamically.
Warfarin (Coumadin, Jantoven) may increase bleeding risk; monitor INR closely during coadministration.
Macrolide antibiotics such as clarithromycin and erythromycin may alter gut flora or have additive effects.
Antiviral agents like ritonavir and saquinavir may modify rifaximin pharmacokinetics or microbial effects.
Antiarrhythmic and blood pressure drugs including amiodarone, quinidine, and verapamil may have additive QT effects when combined.
Potential interactions with other antibiotics resulting in additive gastrointestinal adverse effects.
Drugs altering gut motility or flora may impact rifaximin efficacy.
Concurrent use with other minimally absorbed antibiotics requires careful clinical assessment.
Use with caution alongside medications metabolized by hepatic enzymes due to unknown interaction potential.
Patients should inform clinicians of all over-the-counter, vitamin, and herbal supplement use to assess interaction risks.
Interactions are primarily pharmacodynamic due to minimal systemic absorption but may affect clinical outcomes.
No significant systemic cytochrome P450 enzyme induction or inhibition observed with rifaximin.
Monitor for signs of increased adverse effects or diminished therapeutic effects during combined therapy.
Adjust treatment regimens as necessary based on clinical response and adverse event monitoring.

Preparations Of The Drug

Oral tablets containing 200 mg rifaximin for adult and adolescent dosing, taken three times daily.
Oral tablets containing 550 mg rifaximin formulated for hepatic encephalopathy and IBS-D treatment schedules.
Tablets are film-coated to improve stability and ease of swallowing.
Formulated for minimal systemic absorption to target intestinal infections.
Packaged in blister cards or bottles according to regulatory standards to ensure dose accuracy.
Stored at controlled room temperature away from moisture and excessive heat to maintain efficacy.
Available with patient information leaflets detailing dosing instructions, precautions, and adverse effects.
Available through prescription only, reflecting their antimicrobial and targeted therapeutic use.
Manufactured by licensed pharmaceutical companies under strict quality assurance standards.
Packaging designed to preserve drug integrity during shipping and storage.
Formulations designed to be compatible with coadministration of other gastrointestinal therapies.
Dosage strengths and number of tablets per package vary depending on indication and treatment duration.
Patient adherence is facilitated by clear labeling and flexible dosing without food restrictions.
Developed to minimize potential for drug degradation through gastric acid resistance technology.
Includes educational materials for patients on proper use and completion of therapy.